Editor: What To Know
- IRRAS), a commercial-stage medical technology company focused on developing and commercializing innovative solutions for neurocritical care, announced that they received a response from G-MED, its designated European Notified Body, that requests clarifications and additional information regarding the company’s CE Mark re-certification of IRRAflow Catheter.
- Having established a productive dialogue with the notified body, we now have a clear path forward, and we anticipate responding shortly to the list of questions.
- In the meantime, the launch of IRRAflow in the United States is on track since our 510(k) clearance last year, and our plans to open other global markets remain unchanged.
IRRAflow Catheter CE Mark Re-Certification Update:
Today IRRAS AB (Nasdaq First North Premier: IRRAS), a commercial-stage medical technology company focused on developing and commercializing innovative solutions for neurocritical care, announced that they received a response from G-MED, its designated European Notified Body, that requests clarifications and additional information regarding the company’s CE Mark re-certification of IRRAflow Catheter.
G-MED has asked for additional technical clarifications and updates of certain previous older reports performed by the previous Swedish development partner. The requests are part of the routine review cycle and will be addressed by IRRAS in a timely manner.
“We finally received the feedback from G-MED after a lengthy period,” said Kleanthis G. Xanthopoulos, Ph.D, President and CEO of IRRAS. “We believe that all of their comments are addressable. Having established a productive dialogue with the notified body, we now have a clear path forward, and we anticipate responding shortly to the list of questions. We will continue to work closely with the G-MED team to reintroduce this innovative medical device to the EU market, offering patients, neurosurgeons, and hospitals an effective, intelligent solution to treat intracranial bleeding. In the meantime, the launch of IRRAflow in the United States is on track since our 510(k) clearance last year, and our plans to open other global markets remain unchanged.”
